NCT07467772 2026-03-12
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
Dana-Farber Cancer Institute
Stemline Therapeutics, Inc.
Dana-Farber Cancer Institute
Carrick Therapeutics Limited
Stemline Therapeutics, Inc.
Context Therapeutics Inc.
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc.